Search - tctmd.com

Displaying 321 - 340 of 457

Sort: Relevancy | Date

News Conference News EuroPCR 2014

Benefit of LAA Closure Becomes Most Evident After 1 Year

Caitlin E. Cox

May 23, 2014

Presentation EuroPCR 2014

Predictors of nonresponse to renal denervation in a real world population of patients with uncontrolled hypertension: Analysis of the Global SYMPLICITY Registry

Presenter: Felix Mahfoud

May 22, 2014

Presentation EuroPCR 2014

Final Five-year Outcomes from the Randomized Comparison of Zotarolimus-eluting Stents With Everolimus-eluting Stents in the RESOLUTE All Comers Trial

Presenter: Stephan Windecker

May 22, 2014

Presentation EuroPCR 2014

Final Five Year Outcomes of the NOBORI2 Trial

Presenter: G.B. Danzi

May 22, 2014

News Conference News EuroPCR 2014

UK Registry Finds Long-Term Survival After TAVR Depends on Patient Characteristics

Caitlin E. Cox

May 22, 2014

News Conference News EuroPCR 2014

SYMPLICITY HTN-3: Predictors of Response Still Relevant After Trial’s Negative Findings

Yael L. Maxwell

May 22, 2014

News Conference News EuroPCR 2014

Global SYMPLICITY Substudy Teases out Reasons for Non-response in Real-World Patients

Yael L. Maxwell

May 22, 2014

News Conference News EuroPCR 2014

Early Data Show Novel Catheter-Implanted Device Benefits Patients with Left Heart Failure

Caitlin E. Cox

May 22, 2014

Presentation EuroPCR 2014

Two-year clinical outcome after left atrial appendage closure with the Amplatzer Cardiac Plug device in patients with non-valvular atrial fibrillation and contraindications for anticoagulation therapy

Presenter: Jos? Ram?n L?pez-M?nguez

May 21, 2014

$Routine bivalirudin is superior to unfractionated heparin + bailout GP IIb/IIIa inhibitors in patients with STEMI transported for primary PCI: A prespecified subgroup analysis of the EUROMAX trial$

Presentation EuroPCR 2014

Routine bivalirudin is superior to unfractionated heparin + bailout GP IIb/IIIa inhibitors in patients with STEMI transported for primary PCI: A prespecified subgroup analysis of the EUROMAX trial

Presenter: Uwe Zeymer

May 21, 2014

Presentation EuroPCR 2014

Post‐Market Surveillance Study of Paclitaxel‐Eluting Nitinol Stents for Treating FemoropoplitealArtery Disease in Japan: 12‐Month Results

Presenter: Hiroyoshi Yokoi

May 21, 2014

News Conference News EuroPCR 2014

PARIS Registry: Sex Disparity in DAPT Cessation Arises from Comorbidities

Yael L. Maxwell

May 21, 2014

News Conference News EuroPCR 2014

EuroPCR Features PAD Therapies in Early Development and Real-World Use

Caitlin E. Cox

May 21, 2014

News Conference News EuroPCR 2014

EUROMAX Subanalysis: Bivalirudin Bests Heparin Regardless of GPI Use in STEMI

Yael L. Maxwell

May 21, 2014

News Conference News EuroPCR 2014

BABILON: Drug-Eluting Balloon a Risky Choice for Treating Bifurcation Lesions

Caitlin E. Cox

May 21, 2014

Presentation EuroPCR 2014

BABILON TRIAL: A prospective randomized study of the paclitaxel-coated balloon catheter in bifurcated coronary lesions

Presenter: Jos? Ram?n L?pez-M?nguez

May 20, 2014

Presentation EuroPCR 2014

Primary Results of the Multicenter COBRA Trial

Presenter: Christophe Dubois

May 20, 2014

Presentation EuroPCR 2014

Left Atrial Decompression Through Unidirectional Left-to-Right Shunt for the Treatment of Left Cardiac Failure: Initial Experience with the V-Wave Device

Presenter: Josep Rod?s-Cabau

May 20, 2014

News Conference News EuroPCR 2014

Despite Some Good News, Dedicated Stents Fail to Surpass Standard Care for Bifurcation Lesions

Caitlin E. Cox

May 20, 2014

News Conference News EuroPCR 2014

CENTURY II: Bioresorbable Polymer DES Stands up to Everolimus-Eluting Device

Caitlin E. Cox

May 20, 2014

Advertisement

Benefit of LAA Closure Becomes Most Evident After 1 Year

Predictors of nonresponse to renal denervation in a real world population of patients with uncontrolled hypertension: Analysis of the Global SYMPLICITY Registry

Final Five-year Outcomes from the Randomized Comparison of Zotarolimus-eluting Stents With Everolimus-eluting Stents in the RESOLUTE All Comers Trial

Final Five Year Outcomes of the NOBORI2 Trial

UK Registry Finds Long-Term Survival After TAVR Depends on Patient Characteristics

SYMPLICITY HTN-3: Predictors of Response Still Relevant After Trial’s Negative Findings

Global SYMPLICITY Substudy Teases out Reasons for Non-response in Real-World Patients

Early Data Show Novel Catheter-Implanted Device Benefits Patients with Left Heart Failure

Two-year clinical outcome after left atrial appendage closure with the Amplatzer Cardiac Plug device in patients with non-valvular atrial fibrillation and contraindications for anticoagulation therapy

Routine bivalirudin is superior to unfractionated heparin + bailout GP IIb/IIIa inhibitors in patients with STEMI transported for primary PCI: A prespecified subgroup analysis of the EUROMAX trial

Post‐Market Surveillance Study of Paclitaxel‐Eluting Nitinol Stents for Treating FemoropoplitealArtery Disease in Japan: 12‐Month Results

PARIS Registry: Sex Disparity in DAPT Cessation Arises from Comorbidities

EuroPCR Features PAD Therapies in Early Development and Real-World Use

EUROMAX Subanalysis: Bivalirudin Bests Heparin Regardless of GPI Use in STEMI

BABILON: Drug-Eluting Balloon a Risky Choice for Treating Bifurcation Lesions

BABILON TRIAL: A prospective randomized study of the paclitaxel-coated balloon catheter in bifurcated coronary lesions

Primary Results of the Multicenter COBRA Trial

Left Atrial Decompression Through Unidirectional Left-to-Right Shunt for the Treatment of Left Cardiac Failure: Initial Experience with the V-Wave Device

Despite Some Good News, Dedicated Stents Fail to Surpass Standard Care for Bifurcation Lesions

CENTURY II: Bioresorbable Polymer DES Stands up to Everolimus-Eluting Device

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content